Harrow announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. The U.S. commercial rights to VIGAMOX were purchased by Harrow in January of 2023, and VIGAMOX is the fourth FDA-approved ophthalmic product from that acquisition to have completed the NDA transfer process and become commercially available under the Harrow name. Product orders for VIGAMOX can be made directly through Harrow?s dedicated customer service ordering partner, Cardinal?s Cordlogistics, which includes a wholesaler distribution system encompassing McKesson and AmerisourceBergen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.07 USD | +4.05% | +15.06% | +7.77% |
May. 13 | Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours | MT |
Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.77% | 410M | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Harrow Launches VIGAMOX in the U.S